Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$11.44 USD
+0.19 (1.69%)
Updated Aug 5, 2025 04:00 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZVRA 11.44 +0.19(1.69%)
Will ZVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Other News for ZVRA
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA ...
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call | ZVRA Stock News
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to ...
ZVRA: Zevra Therapeutics Seeks EMA Approval for NPC Drug Arimoclomol
Zevra Therapeutics submits MAA to EMA for evaluation of arimoclomol